Cathelicidin Antimicrobial Peptides Show Promise for Skin Diseases but Face Major Hurdles in Clinical Translation | Research

The takeaway

Cathelicidins like LL-37 show therapeutic potential for skin infections, melanoma, acne, and diabetic wounds, but clinical translation is hampered by unclear efficacy in trials, bacterial resistance, stability issues, and manufacturing challenges.

Multiple clinical trial failures for peptide therapies
Despite strong preclinical promise, many cathelicidin and related peptide-based therapies have failed in clinical trials — highlighting the significant gap between laboratory antimicrobial activity and real-world therapeutic efficacy for skin conditions.

What the researchers found

The review identifies cathelicidins' therapeutic potential across multiple skin conditions:

- **Infections**: Broad-spectrum activity against bacteria, viruses, and fungi, including antibiotic-resistant strains

- **Wound healing**: LL-37 promotes wound closure and skin barrier restoration, particularly relevant for diabetic foot ulcers

- **Cancer**: Some cathelicidins show anti-melanoma activity

- **Acne**: Antimicrobial and anti-inflammatory effects relevant to acne pathology

However, significant translational barriers exist: many peptide therapies have failed clinical trials due to unclear efficacy and safety; bacterial resistance to cathelicidins has emerged (contradicting initial claims); large-scale production is costly; drug stability and delivery formulation remain challenging.

Why it matters

As antibiotic resistance becomes a global crisis, the need for new antimicrobial approaches has never been greater. Cathelicidins offer a fundamentally different mechanism from conventional antibiotics and could address hard-to-treat skin infections. However, the honest assessment of clinical translation challenges presented here — including the uncomfortable truth about bacterial resistance developing against these 'natural' antibiotics — is essential for directing research resources effectively.

How the study worked

This is a comprehensive review of published research on cathelicidin antimicrobial peptides, their biological functions in skin immunity, therapeutic applications for skin diseases, and the challenges preventing clinical translation. The authors examine evidence from preclinical studies, clinical trial outcomes, and pharmaceutical development literature.

What this study cannot tell us

As a review, no new experimental data is presented. The therapeutic applications discussed are largely based on preclinical data, with limited successful clinical translation. The review acknowledges but does not fully resolve the tension between cathelicidins' dual roles as antimicrobials and pro-inflammatory mediators (particularly relevant in conditions like rosacea where LL-37 overexpression is pathological). Specific clinical trial failure details and success rates are not quantified.

How to read the evidence

This is a narrative review synthesizing preclinical research, clinical trial outcomes, and pharmaceutical development challenges. The underlying evidence for cathelicidin biological activity is strong, but the evidence for clinical therapeutic use is limited due to the translational challenges the review describes.

When this study was published

Published in 2024, this review provides a current and balanced assessment of where cathelicidin therapeutics stand. The field continues to evolve with new peptide engineering approaches and delivery technologies.

The bigger picture

Antimicrobial peptides were once hailed as the solution to antibiotic resistance because bacteria were thought to be unable to develop resistance against them. This review acknowledges that this claim was overly optimistic — resistance does develop. This honest reassessment is reshaping the field, pushing researchers toward combination approaches, peptide modifications, and novel delivery systems rather than relying on natural cathelicidins alone.

Questions still open

Can engineered cathelicidin analogs overcome the resistance and stability issues that have plagued natural peptide therapeutics?
Would topical formulations (gels, nanoparticles, wound dressings) solve the delivery and stability challenges for skin applications?
Could combination therapy — cathelicidins plus conventional antibiotics — prevent resistance development while enhancing efficacy?

Common questions

What is LL-37 and why is it important for skin health?

LL-37 is the only cathelicidin antimicrobial peptide produced by humans. It's made by immune cells and skin cells and serves as a front-line defense against bacteria, viruses, and fungi on the skin. Beyond killing pathogens, LL-37 helps wounds heal, maintains the skin barrier, and modulates inflammation. Abnormal LL-37 levels are linked to skin diseases — too little increases infection risk, while too much (as in rosacea) causes inflammation.

Why haven't antimicrobial peptides replaced antibiotics if they're so effective in the lab?

Several real-world challenges have slowed progress: (1) Peptides are expensive to manufacture at scale; (2) They break down easily in the body, requiring special formulations; (3) Despite early claims, bacteria can develop resistance to them; (4) Many peptides that kill bacteria in a test tube don't work as well in actual wounds or skin. This review honestly addresses these challenges, which is essential for directing future research toward solutions.

Read the original research

Cathelicidins: Opportunities and Challenges in Skin Therapeutics and Clinical Translation.

Antibiotics (Basel, Switzerland), 14(1)

View on PubMed ↗Publisher’s paper ↗

Citation

Dzurová, Lenka; Holásková, Edita; Pospíšilová, Hana; Schneider Rauber, Gabriela; Frébortová, Jitka. (2024). Cathelicidins: Opportunities and Challenges in Skin Therapeutics and Clinical Translation.. Antibiotics (Basel, Switzerland), 14(1). https://doi.org/10.3390/antibiotics14010001